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In the last few years, implementation of prevention and 
control measures has significantly reduced the burden of tropical 
protozoan diseases such as human African trypanosomiasis 
(HAT or sleeping sickness) and malaria. However, approximately 
70 million people remain at risk of HAT, and in the case of 
malaria, half of the world’s population live in countries where the 
disease is endemic. Thus, these parasitic infections continue to 
pose a serious health threat, especially in developing regions.1,2 
The causative agents of HAT and malaria are the single-celled 
parasites Trypanosoma brucei gambiense or T. brucei 
rhodesiense, and several species of the genus Plasmodium, 
amongst which, P. falciparum is the most common and deadly. 
The parasites are transmitted through the bite of infected insects, 
namely Glossina flies (tsetse flies) for HAT and Anopheles 
mosquitoes for malaria.  
In HAT, following an initial hemolymphatic phase, parasites 
can cross the blood‒brain barrier (BBB) and infect the central 
nervous system (CNS), leading to severe neurological symptoms. 
Without treatment, death is inevitable when the disease has 
reached this late stage. In malaria, the parasites multiply initially 
in the liver, and then in the bloodstream. In severe cases, they can 
become sequestered within brain capillaries, particularly in 
children, causing the so-called cerebral malaria, frequently with 
fatal consequences. 
Current options to reduce the burden of HAT and malaria are 
far from ideal.3-5 There is no licensed vaccine for either infection, 
with vector control and public health measures being the main 
means of prevention. Currently registered drugs are problematic, 
with toxicity and resistance being major problems. For example, 
although five drugs have been approved for the treatment of HAT 
(pentamidine, suramin, melarsoprol, nifurtimox and eflornithine), 
their activity can be stage and/or species specific, they display a 
range of toxic side effects, and require strict and complicated 
parenteral administration regimens.6 This type of specialized 
infrastructure is often unavailable in the poor rural settings where 
HAT is endemic. Drug resistance continues to emerge and 
undermine clinical effectiveness. Increased resistance has been 
observed for the trypanocidal agent melarsoprol. In the case of 
malaria, chloroquine is no longer widely effective and rising 
resistance against the current front line drug artemisinin is a 
potential threat to global health. Overall, there is an acute need to 
ART I CLE  I NFO  AB ST R ACT  
Article history: 
Received 
Revised 
Accepted 
Available online 
We have synthesized a series of dimers of (+)-(7R,11R)-huprine Y and evaluated their activity 
against Trypanosoma brucei, Plasmodium falciparum, rat myoblast L6 cells and human 
acetylcholinesterase (hAChE), and their brain permeability. Most dimers have more potent and 
selective trypanocidal activity than huprine Y and are brain permeable, but they are devoid of 
antimalarial activity and remain active against hAChE. Lead optimization will focus on 
identifying compounds with a more favourable trypanocidal/anticholinesterase activity ratio. 
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develop novel drugs for HAT and malaria that can circumvent 
the limitations of existing therapies. 
Several approaches have been proposed to speed up the 
antiprotozoal drug pipeline. These include high-throughput 
screening of large compound libraries, new strategies to 
functionally validate novel druggable targets involved in key 
steps of the parasite life-cycle,7-10 or the simultaneous inhibition 
of two or more key biological targets with combination therapies 
or multitarget-directed ligands.11-13 Increasingly,  the search for 
novel antiprotozoal agents also involves the repositioning of 
existing drugs registered for other applications14 or the synthesis 
of new chemical entities endowed with antiprotozoal activity.15-17  
In recent years, new compounds bearing the 4-amino-7-
chloroquinoline core of chloroquine, or other aminoquinoline 
moieties, have been assessed as novel trypanocidal or 
antimalarial agents, or as dual agents endowed with both 
activities.18-21 The development of single molecules that have 
potency against different protozoan diseases (such as HAT and 
malaria) has been regarded as an feasible approach, with 
potential economic savings.22 We recently reported that the 
aminoquinoline derivatives huprines, a structural class initially 
developed as inhibitors of the enzyme acetylcholinesterase, are 
moderately effective and selective trypanocidal agents, with 
some also being active against a chloroquine-resistant strain of P. 
falciparum.23,24 In particular, the 4-amino-7-chloroquinoline 
derivative 1 (huprine Y, Scheme 1) exhibited the lowest IC50 
value of the series against T. brucei (IC50 = 0.61 µM; IC90 = 2.94 
µM), with one of the best selectivity indices over rat myoblast L6 
cells (SI = 13) among the entire set of tested huprines.23 
Molecular dimerization of compounds with known 
antiprotozoal activity constitutes a strategy that can be used to 
overcome drug resistance.25 This approach has proven successful 
for dimers of 4-aminoquinolines, in which the two constituting 
units were connected through linkers of different length or 
containing different functional groups.26-29 
Here, we report the synthesis of dimers of huprine Y, in which 
the two huprine moieties have been connected through 
oligomethylene linkers of different length, or with a p-phenylene-
bis(methylene) tether. To this end, enantiopure (+)-(7R,11R)-
huprine Y [(7R,11R)-1, Scheme 1], the least active enantiomer in 
terms of acetylcholinesterase (AChE) inhibition activity,30-32 has  
been used. The dimeric bis(+)-huprines have been tested against 
cultured bloodstream forms of T. brucei and P. falciparum, and 
their cytotoxicity against mammalian cells, inhibitory activity 
against human AChE, and brain permeability have been assessed. 
The synthesis of hexa-, octa-, deca-, and dodeca-methylene 
linked bis-huprines (+)-2a‒d and the p-phenylene-
bis(methylene)-linked bis-huprine (+)-2e was carried out by 
reaction of 2 equivalents of (+)-(7R,11R)-huprine Y with 1 
equivalent of the corresponding α,ω-dihaloalkane, using KOH as 
the base in DMSO at room temperature for three days (Scheme 
1). After silica gel column chromatography purification, bis(+)-
huprines (+)-2a‒d were obtained in moderate yields (21‒50% 
yields, whereas (+)-2e was obtained in a lower yield (11%) along 
with the byproduct resulting from the monoalkylation of (+)-1 
(12% yield). 
Bis-huprines (+)-2a‒e were converted into the corresponding 
dihydrochlorides for their chemical characterization (specific 
rotation, melting point, IR, 1H and 13C NMR, HRMS, and 
elemental analysis) and biological profiling.33 
 
 
 
Scheme 1. Reagents and conditions: (a) (+)-1 (2 equiv.), 
KOH, DMSO, 2 h; then, α,ω-dihaloalkane (1 equiv.) in 
DMSO, rt, 3 days. 
 
Bis-huprines (+)-2a‒e were first tested in vitro against 
cultured bloodstream forms of T. brucei. All of the bis-huprines 
exhibited IC50 values in the range 0.50‒0.89 µM. Their IC90 
values of around 1 µM (0.73‒1.09 µM) (Table 1), were 
significantly lower than the parent huprine Y (IC90 = 2.94 µM). 
Given the narrow range of potencies of the different bis-huprines, 
the length of the linker or the presence of a benzene ring within 
the linker do not seem to have a strong influence on the 
trypanocidal activity of bis(+)-huprines. Thus, the increased 
trypanocidal potency of bis-huprines, relative to huprine Y, might 
be ascribed to the dimerization strategy, even though the 
mechanisms responsible for inhibition of trypanosome growth or 
for the enhanced activity are not known. 
Bis-huprines (+)-2a‒e were also evaluated against the 
chloroquine-resistant K1 strain of P. falciparum. Even though 
some huprines have been reported to exhibit moderately potent 
antiplasmodial properties,23 huprine Y did not exhibit significant 
activity (IC50 > 10 µM). Huprine Y bears the 4-amino-7-
chloroquinoline moiety, thought to be an antimalarial 
pharmacophore responsible for inhibition of heme 
dimerization.20,34 Since dimerization of other 4-aminoquinoline 
compounds increased antiplasmodial potency and/or overcame 
the chloroquine resistance mechanism,26-29 we hypothesized that 
dimerization of huprine Y to bis-huprines (+)-2a‒e might also 
enhance activity. However, no noticeably increased 
antiplasmodial potency was observed for the dimeric compounds, 
which exhibited IC50 values > 5 µg/mL (i.e. > 6‒7 µM), much 
higher than that of artemisinin (IC50 = 91 nM) used in this assay 
as a positive control. The improvement of potency against 
chloroquine resistant strains of P. falciparum of other bis(4-
aminoquinoline) derivatives relative to the corresponding 
monomeric compounds has been ascribed mainly to the doubling 
of the number of protonatable nitrogen atoms in the dimers, 
which might lead to more efficient trapping in the acidic 
digestive vacuole of the parasite and prevention of heme 
polymerization.25,29 The failure of bis-huprines to show 
antiplasmodial activity might be indicative of the fact that these 
compounds cannot hit the biological target of chloroquine and 
other 4-aminoquinoline derivatives despite their structural 
similarity. Indeed, we have recently found that the parent huprine 
Y, unlike chloroquine, shows no inhibition of β-haematin 
formation, whereas several huprine analogues that possess 
antiplasmodial activity are effective inhibitors of β-haematin 
formation (unpublished results). 
Table 1 
Trypanocidal, cytotoxic and hAChE inhibitory activity of bis-
huprines (+)-2a‒ea 
Compd T. brucei 
IC50 µM 
T. brucei 
IC90 µM 
L6 cells 
IC50 µM 
SIb hAChE 
IC50 nM 
(+)-2a 0.89 ± 0.02 1.09 ± 0.01 1.61 ± 0.07 1.8 192 ± 18 
(+)-2b 0.52 ± 0.01 0.74 ± 0.02 4.92 ± 0.15 9.5 72.5 ± 8.3 
(+)-2c 0.50 ± 0.01 0.73 ± 0.01 7.71 ± 0.70 15.4 17.5 ± 3.8 
(+)-2d 0.76 ± 0.03 0.99 ± 0.05 28.5 ± 2.9 37.5 431 ± 22 
(+)-2e 0.57 ± 0.02 0.75 ± 0.02 16.1 ± 0.3 28.2 ndc 
1 0.61 ± 0.03d 2.94 ± 0.20d 7.80 ± 
0.47d 
12.8 0.61 ± 0.03e 
a
 In vitro activity against bloodstream form of T. brucei (pH 7.4) and rat 
myoblast L6 cells expressed at the concentration that inhibited growth by 
50% (IC50) and 90% (IC90, for trypanocidal activity). Data are the mean of 
triplicate experiments ± SEM. 
b
 SI: Selectivity index is the ratio of cytotoxic to trypanocidal IC50 values. 
c
 Not determined. 
d
 Taken from ref. 23. 
e
 Taken from ref 35. 
 
The cytotoxicity of bis-huprines was assessed in vitro using 
rat skeletal myoblast L6 cells. These compounds displayed a 
modest toxicity against the mammalian cells, exhibiting IC50 
values in the range 1.6‒28.5 µM (Table 1). A clear structure-
cytotoxicity trend was found, with cytotoxicity decreasing with 
increased tether length and with the presence of a benzene ring 
within the linker. Thus, the dodecamethylene-linked bis-huprine 
(+)-2d was found to be 18-, 6-, and 4-fold less cytotoxic than the 
hexa-, octa-, and deca-methylene counterparts (+)-2a, (+)-2b, and 
(+)-2c, respectively, whereas the p-phenylene-bis(methylene)-
linked bis-huprine (+)-2e was 10-fold less cytotoxic than the 
oligomethylene-linked bis-huprine with a similar tether length, 
(+)-2a. Thus, the longest homologue (+)-2d and the p-phenylene-
bis(methylene)-linked bis-huprine (+)-2e displayed the highest 
selectivity indices for trypanocidal over cytotoxic activity (SI = 
37.5 and 28.2, respectively). 
Bis-huprines possess two units of (+)-huprine Y, which is the 
distomer for AChE inhibition. Even though the dextrorotatory 
enantiomers of huprine Y and some hybrid derivatives are less 
potent AChE inhibitors than the racemic mixtures and the 
levorotatory counterparts, they typically exhibit activities in the 
nanomolar to low micromolar range.32,35 To assess potential 
toxicity issues arising from AChE inhibition by bis-huprines, 
their inhibitory activity against human recombinant AChE 
(hAChE) was evaluated by the method of Ellman.36 As expected, 
bis-huprines (+)-2a-d are 30-700-fold less potent hAChE 
inhibitors than racemic huprine Y, but they exhibit more potent 
anticholinesterase than trypanocidal activity (2-29-fold), with 
IC50 values for hAChE inhibition in the two-three digit 
nanomolar range (Table 1). The least active compound against 
hAChE is (+)-2d, which is the dimer with the best selectivity 
index for trypanocidal over cytotoxic activity. However, even in 
this case, its 2-fold higher anticholinesterase activity could still 
be a concern in terms of further development. 
Permeability across the BBB is a necessary condition for drug 
candidates against HAT that are to be effective against late-stage 
disease, when the CNS is invaded by the parasite.  
Table 2 
BBB predicted permeabilities of bis-(+)-huprines (+)-2a‒e 
and parent huprine Y 
Compd Pe (10‒6 cm s‒1)a Prediction 
(+)-2a 11.1 ± 0.3 CNS+ 
(+)-2b 13.9 ± 1.0 CNS+ 
(+)-2c 8.7 ± 1.5 CNS+ 
(+)-2d 17.4 ± 0.7 CNS+ 
(+)-2e 8.3 ± 0.6 CNS+ 
huprine Y, 1 23.8 ± 2.7b CNS+ 
a
 Values are expressed as mean ± SD of three independent experiments. 
b
 Taken from ref. 32. 
 
The BBB permeability of bis-huprines (+)-2a‒e was assessed 
in vitro through the widely used parallel artificial membrane 
permeability assay (PAMPA-BBB), using a lipid extract of 
porcine brain as the artificial membrane.37 Assay validation was 
performed by comparing the experimentally observed 
permeabilities [Pe (exp)] of fourteen marketed drugs with the 
permeabilities reported in the literature [Pe (lit)], which provided 
a good linear correlation: Pe (exp) = 1.4974 Pe (lit) ‒ 0.8434 (R2 
= 0.9428). Taking into account this equation and the limits 
established by Di et al.,35 three ranges of BBB permeation were 
established: high BBB permeation (CNS+) for those compounds 
with Pe (10‒6 cm s‒1) > 5.1; low BBB permeation (CNS‒) for 
those compounds with Pe (10‒6 cm s‒1) < 2.1; and uncertain BBB 
permeation (CNS±) for those compounds with 5.1 > Pe (10‒6 cm 
s
‒1) > 2.1. All the bis-huprines exhibited permeabilities clearly 
above the threshold established for high BBB permeation (Table 
2), even though they seem to be less permeable than monomeric 
huprine Y. This may arise because they are dibasic compounds 
and will mostly be in the diprotonated form, whereas monomeric 
huprine, with only one basic nitrogen atom, will be 
monoprotonated under the assay conditions. 
In summary, we report the synthesis of a series of dimeric 
bis(4-aminoquinoline) derivatives, which are composed of two 
units of (+)-(7R,11R)-huprine Y connected through 
oligomethylene linkers of different length or a p-phenylene-
bis(methylene) linker. We also describe the assessment of the 
different bis(+)-huprines on the growth of bloodstream forms of 
T. brucei and P. falciparum, and of rat skeletal myoblast L6 cells, 
as well as their hAChE inhibitory activity and BBB permeability. 
All of the bis(+)-huprines exhibited potent trypanocidal activity, 
with IC50 and IC90 values in the submicromolar range. However, 
they did not exhibit significant antiplasmodial activity, and, 
conversely, they were found to potently inhibit hAChE. As 
trypanocidal agents, bis(+)-huprines are more potent than 
monomeric huprine Y and some of them, particularly the 
dodecamethylene- and p-phenylene-bis(methylene)-linked dimers 
(+)-2d and (+)-2e, are less cytotoxic and, hence, more selective 
for T. brucei over rat L6 cells growth inhibition than huprine Y. 
All the bis(+)-huprines have been predicted to have the ability to 
cross the BBB, thereby being potentially useful for the treatment 
of late-stage HAT. Overall, bis(+)-huprines (+)-2d and (+)-2e 
emerge as interesting lead compounds for further trypanocidal 
drug development. Future research should focus not only on 
increasing trypanocidal potency, but decreasing cytotoxicity and 
AChE inhibitory activity. 
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